Among patients with NF1, significantly lower 5-year DSS rates were found among those with undifferentiated pleomorphic sarcomas (UPSs; 1 of 5 patients; [20.0%]), HGG (8 of 34 patients [23.1%]), MPNST (72 of 228 patients [31.6%]), ovarian carcinoma (4 of 7 patients [57.1%]), and melanoma (8 of 12 patients [66.7%]) compared with those who had neoplasms classified as other (110 of 119 patients [92.4%]) (all P < .001) (Table 2; Figure 2). This evidence concerns the gene NF1 and melanoma.